71
As antiretroviral therapy (ART) prolongs lifespans, people with HIV (PWH) face a new syndemic: Cardiovascular-Kidney-Metabolic (CKM) syndrome. Yet CKM in PWH is poorly characterized. Inflammation, complex pharmacokinetic alterations, ART-associated metabolic effects, and gut dysbiosis amplify risk. Managing CKM increases medication burden, thereby heightening the risk of drug–drug interactions and adverse drug effects. Therefore, CKM in PWH represents an emerging clinical pharmacology priority.
A perspective, published in Clinical Pharmacology & Therapeuticsoutlines gaps and challenges and call for CKM research in PWH.
Source : Clinical Pharmacology & Therapeutics
